Health Technology Assessment Nucleus (NATS) nested in reference hospitals nationwide distributed in Brazil were created in 2011-2012. Hospital de Clinicas de Porto Alegre (HCPA) a reference university public hospital in the southernmost province of Brazil stablished its nucleus in 2012, before this decentralized committees performed HTA evaluations. OBJECTIVES: Evaluate the results of NATS implementation at HCPA, by reviewing its technical production and analyzing the decisions referent to incorporations requests. METHODS: We reviewed all requests for inclusion of health technologies sent to NATS and Drugs and Therapeutics Committee (COMEDI) since October, 2012. The database evaluated included the online requests of health technologies filled during the time and the register of both committee meetings. The results of the requests for health technologies inclusion were categorized as accepted or rejected and also classified (according UK-NHS Innovation Center criteria and to ‘Morgan et al’ criteria) as innovation or not.  RESULTS: During the period of time (Oct/2012-Dec/2016) there were in total 75 requests for inclusion of new health technologies (equipment, vaccines, health products and medicines) in the HCPA. Thirty-three of these requests concern the inclusion of equipment, vaccines or ‘health products’ and forty were related to medicines. Of the 73 requests 30 (13 equipment/vaccines/health products and 17 medicines) were accepted— 41% of all requests. Also 41% of all inclusion requests regarded innovative products and 43% of all incorporated technologies were considered innovations. CONCLUSIONS: Of all requests for health technology inclusion, less than half were accepted after evaluation. Considering the aspect innovation only 43% of incorporated health technologies represented innovative products, this proportion was even lower between the medicines. Possible causes are the high cost of these products and what does the term innovation could represent, notable when discussing innovate drugs—the variability of the ‘level’ of innovation is an important variable to consider.